Menlo Park, United States
Avails Medical, Inc. is a pioneering company in the health care and medical devices industries, focused on providing affordable and rapid solutions for antibiotic susceptibility testing (AST) in clinical laboratories. Founded in 2013 by a team of postdoctoral researchers from Stanford, Avails Medical's electronic biosensor technology aims to streamline the process of pathogen quantification and susceptibility testing in human specimens, eliminating time-consuming culturing steps.
The company's eQUANT(TM) platform, which has garnered a $1.70M grant investment from CARB-X as of 01 September 2022, automates the generation of a 0.5 McFarland equivalent (eMcF) directly from positive blood cultures, effectively cutting 18+ hours from the standard workflow by eliminating the need for subcultures. Notably, Avails' eQUANT system is FDA 510(k) cleared.
Furthermore, Avails Medical is actively developing a rapid phenotypic AST platform designed for use directly from positive blood cultures as well as cultured isolates. The company's electrical biosensor platform is designed to seamlessly integrate into existing laboratory workflows and budgets, catering to clinical laboratories of varying sizes, from community hospitals to academic centers and centralized facilities.
Xagenic
